Research
Latest published research we're tracking.
The newest skincare and haircare papers from PubMed, linked to the ingredients we decode. Summaries are the authors' own abstracts — we excerpt, attribute, and link out to the source.
374 papers
Efficacy of shortwave radiofrequency-assisted delivery of Quhong Zhiyang ointment in the treatment of facial seborrheic dermatitis: a retrospective study of 72 patients.
Cutaneous and ocular toxicology · 2026
OBJECTIVE: To observe the clinical efficacy of Quhong Zhiyang ointment via shortwave radiofrequency-assisted delivery in the treatment of facial seborrheic dermatitis. METHODS: Seventy-two individuals who were diagnosed with seborrheic dermatitis and who received treatment and completed a 3-month follow-up period were enrolled in this retrospective analysis, with 36 patients in each group. The… Read on PubMed →
T Cell Immunosenescence in Inflammatory Skin Diseases: Pathogenesis and Therapeutic Targets.
Aging cell · 2026
T cell immunosenescence refers to the progressive functional decline of T lymphocytes with aging, characterized by the phenotypic markers, mitochondrial dysfunction, and the senescence-associated secretory phenotype (SASP), representing a pivotal aspect of overall immune aging. This review systematically elucidates the critical role of T cell immunosenescence in the pathogenesis of common… Read on PubMed →
Practical considerations for managing patients being treated with topical roflumilast.
Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques · 2026
Topical roflumilast, available in 0.3% cream, 0.15% cream, and 0.3% foam formulations, is a novel, highly potent phosphodiesterase-4 (PDE4) inhibitor that was recently approved in Canada for the treatment of plaque psoriasis, atopic dermatitis, and seborrheic dermatitis, respectively. Topical formulations were shown in clinical trials to significantly improve disease symptoms with excellent… Read on PubMed →
Atopic dermatitis reconsidered: Clinical mimics and diagnostic pearls.
Journal of the American Academy of Dermatology · 2026
Atopic dermatitis (AD) is a chronic, pruritic inflammatory skin condition with a complex pathogenesis and variable clinical presentation, often overlapping with other dermatologic diseases. This article considers the differential diagnoses for AD, emphasizing the importance of accurately distinguishing it from both common and rare conditions. Among inflammatory dermatoses, seborrheic dermatitis… Read on PubMed →
Assessing the safety of topical minoxidil through disproportionality analysis of FAERS reports.
Expert opinion on drug safety · 2026
BACKGROUND: Topical minoxidil, approved by the FDA in the 1980s, has been widely used to manage androgenetic alopecia. While effective, several adverse events (AEs) related to its use, especially those not well-documented on product labels, remain a concern. OBJECTIVE: This study aimed to evaluate the safety of topical minoxidil by analyzing AEs reported in the FDA Adverse Event Reporting System… Read on PubMed →
Randomized Controlled Trial of the Topical Jak Inhibitor Delgocitinib Cream in Patients with Frontal Fibrosing Alopecia.
The Journal of investigative dermatology · 2026
BACKGROUND: Frontal fibrosing alopecia (FFA) is a cicatricial alopecia with generally poor prognosis if untreated and no approved treatment options. OBJECTIVE: The aim of this study was to evaluate changes in the molecular signature of FFA lesions after application of delgocitinib cream. Safety, tolerability, and efficacy were also investigated. METHODS: This was a phase 2a, randomized… Read on PubMed →
Low-Dose Oral Minoxidil as Treatment for COVID-19-Related Telogen Effluvium: Results From a Retrospective Series of 69 Patients.
Actas dermo-sifiliograficas · 2026
BACKGROUND AND OBJECTIVE: Coronavirus disease 2019 (COVID-19) associated telogen effluvium (CATE) has been observed in patients after infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Although it is self-limiting, hair loss can be very distressing, and some patients may seek medical treatment to help promote hair regrowth. Low-dose oral minoxidil (LDOM) has emerged as a… Read on PubMed →
Safety and tolerability of combination oral spironolactone and low-dose oral minoxidil for hair loss in adult females: A retrospective cohort study.
Journal of the American Academy of Dermatology · 2026
BACKGROUND: Spironolactone and oral minoxidil are effective female alopecia monotherapies. Combination therapy is commonly used, though safety and tolerability data are limited. OBJECTIVE: To assess safety and tolerability by adverse effect incidence. METHODS: Retrospective cohort study conducted in females aged ≥18 taking combination therapy for hair loss. RESULTS: A total of 432 patients were… Read on PubMed →
Prescribing Habits for Androgenetic Alopecia Among Dermatologists in Spain in 2024: A Cross-Sectional Study.
Actas dermo-sifiliograficas · 2026
The management of androgenetic alopecia (AGA) is evolving. This study updates current prescribing practices compared with 2019-2020. A digital survey was conducted among dermatologists in Spain between March and June 2024, focusing on AGA treatment trends, nutricosmetic product selection, and the adoption of hair skinification. A total of 202 dermatologists participated, including 164 attending… Read on PubMed →
Adjunctive approaches for androgenetic alopecia: A clinical review of nutritional, light-based, topical, and lifestyle interventions.
Journal of the American Academy of Dermatology · 2026
Androgenetic alopecia (AGA) is a chronic, progressive condition with limited Food and Drug Administration-approved treatments. Therefore, there is increasing interest in adjunctive options among patients and physicians. This clinical review synthesizes and critically appraises current evidence on nutritional supplements and nutraceuticals, light-based therapies, topical agents, and lifestyle… Read on PubMed →
Efficacy of polyphenolic compounds for hair regeneration: a systematic review and meta-analysis of randomized controlled trials.
The Journal of dermatological treatment · 2026
BACKGROUND: Non-scarring alopecia, including androgenetic alopecia, alopecia areata, and telogen effluvium, is highly prevalent and often associated with significant psychosocial burden. Although treatments such as minoxidil and finasteride are available, variability in response and tolerability concerns have increased interest in alternative therapeutic approaches. Polyphenolic compounds have… Read on PubMed →
Exploring the efficacy evaluation model for androgenic alopecia using hair organoids: Transcending conventional hair research.
Journal of dermatological science · 2026
BACKGROUND: The development of effective evaluation tools for anti-hair loss therapies is critical due to limitations in existing experimental systems. Hairy 3D skin models and hairy skin explants are not yet commercially viable, necessitating alternative approaches for assessing androgenic alopecia (AGA). OBJECTIVE: This study aimed to develop a hair-bearing organoid model derived from embryonic… Read on PubMed →
Enhanced follicular delivery of minoxidil to human scalp skin using cetosomal formulation.
Colloids and surfaces. B, Biointerfaces · 2026
BACKGROUND: Androgenetic alopecia (AGA) is a common condition marked by progressive hair follicle miniaturization, for which topical minoxidil remains a first-line therapy. However, conventional hydroalcoholic formulations are associated with poor scalp retention, rapid drug loss, and local irritation. This study evaluated the follicular targeting, skin retention, and mechanistic behavior of a… Read on PubMed →
Efficacy and Safety of Fractional Laser Therapy for Androgenetic Alopecia: A Systematic Review and Meta-Analysis.
Journal of cosmetic dermatology · 2026
OBJECTIVE: To systematically evaluate the efficacy and safety of fractional laser therapy in the treatment of androgenetic alopecia. METHODS: A comprehensive literature search was conducted in PubMed, Web of Science, Embase, the Cochrane Library, and China National Knowledge Infrastructure (CNKI) from inception to November 2025. Eligible studies were selected according to the PICOS framework. The… Read on PubMed →
Case Report: Dupilumab induced sustained complete remission in a child with severe alopecia areata and markedly elevated IgE.
Frontiers in immunology · 2026
BACKGROUND: Severe alopecia areata in children is difficult to treat, and conventional therapies often show limited efficacy and substantial adverse effects. Dupilumab has shown potential in patients with alopecia areata and an atopic background, and baseline IgE has been proposed as a predictor of response. However, long-term outcomes and maintenance strategies in children with very high IgE… Read on PubMed →
Therapeutic update on alopecia areata: a critical review of standard and emerging targeted therapies.
Inflammopharmacology · 2026
BACKGROUND AND OBJECTIVES: This narrative review provides a comprehensive update on the pathogenesis and therapeutic management of alopecia areata (AA), critically evaluating the transition from non-specific immunosuppression to targeted molecular therapies. METHODS: A literature search was conducted across PubMed, Scopus, and the Cochrane Library (inception to 2024). A strict hierarchy of… Read on PubMed →
Venlafaxine reverses chemotherapy-induced alopecia through epithelial and dermal reprogramming at single-cell resolution.
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2026
Chemotherapy-induced alopecia (CIA) is a frequent and distressing adverse effect of cytotoxic cancer therapy that significantly affects patients' quality of life, yet its cellular mechanisms remain incompletely understood and effective pharmacological interventions are limited. Here, we combined single-cell RNA sequencing with in vivo mouse models and ex vivo human hair follicle organ culture to… Read on PubMed →
Discovery and evaluation of SIPI11594: a novel mitochondrial pyruvate carrier inhibitor with anti-hair loss efficacy.
Bioorganic & medicinal chemistry · 2026
Inhibition of the mitochondrial pyruvate carrier (MPC) is a promising strategy to promote hair follicle stem cell activation via lactate production for treating alopecia. To identify new MPC inhibitors, we designed and synthesized 32 novel α-cyano-4-hydroxycinnamate derivatives based on a N1-arylmethylpyridine compound 4I. Structure-activity relationship analysis identified C4-substitution on the… Read on PubMed →
Case Report: Bimekizumab for dissecting cellulitis of the scalp.
Frontiers in immunology · 2026
Dissecting cellulitis of the scalp (DCS) is a cicatricial alopecia characterized by follicular occlusion that progresses to abscess formation and rupture, driven by an intense inflammatory cascade. Part of the follicular occlusion tetrad, DCS typically presents with painful nodules and interconnecting sinus tracts localized to the scalp. Treatment of this recalcitrant disease is difficult, and… Read on PubMed →
Exosomes in Hair Restoration.
Dermatologic clinics · 2026
Androgenetic alopecia is the most common cause of progressive hair loss and has substantial impact on quality of life. Conventional treatments, including minoxidil and finasteride, are limited by variable response rates and side effects. Exosomes, which are nanosized extracellular vesicles involved in cell-cell communications, have emerged as promising candidates in hair restoration. Preclinical… Read on PubMed →